Key Highlights
- Clover Health (CLOV) stock climbed nearly 14% to close at $4.89 after receiving a Medicare star rating increase to 4.5 Stars from 3.5 Stars by CMS.
- A federal court decision mandated CMS to recalculate the rating for Clover’s PPO Medicare Advantage plan under Contract H5141.
- This enhanced rating impacts 2027 reimbursement rates and opens access to quality bonus payments from CMS.
- Shares reached a new 52-week peak of $5.14 during intraday trading, marking the third consecutive day of gains.
- CLOV’s advance occurred against a backdrop of broader market declines, with the S&P 500, Dow, and Nasdaq all posting losses.
Clover Health (CLOV) stock finished Wednesday’s session up 13.99% at $4.89, reaching an intraday peak of $5.14, following the company’s announcement of a significant Medicare star rating enhancement from the Centers for Medicare & Medicaid Services.
Clover Health Investments, Corp., CLOV
Shares have posted gains for three consecutive sessions and established a new 52-week high during trading.
The driving force: CMS revised CLOV’s 2026 Medicare star rating upward to 4.5 Stars from 3.5 Stars after a court decision in the company’s favor.
This rating adjustment pertains to Contract H5141, Clover’s PPO Medicare Advantage offering, which serves over 97% of its membership base.
The updated rating will have direct implications for 2027 payment schedules, including qualification for quality bonus payments from CMS — representing tangible financial benefits beyond mere reputation.
Court Ruling Drives Rating Revision
The rating modification followed significant legal action. Clover initiated litigation against CMS and the U.S. Department of Health and Human Services, contending the agency had applied “improper” quality measures and calculation methods when determining its initial 3.5-star rating.
Clover maintained the accurate rating should have been 4.0 Stars, asserting the lower rating would have resulted in millions of dollars in lost quality bonuses and government payments, diminished its market position, and hampered expansion plans.
On May 29, 2026, the U.S. District Court for the Southern District of Georgia ruled in Clover’s favor, invalidating the original rating and directing CMS to recalculate.
CMS informed Clover of the revised 4.5-star rating on June 9 — exceeding Clover’s initial request.
Strong Earnings Supporting Rally
The star rating announcement came amid already strengthening fundamentals for the company.
Clover posted its inaugural positive GAAP net income during Q1 2026, accompanied by substantial year-over-year revenue growth.
Canaccord analyst Richard Close recently increased his price target on CLOV while maintaining a Buy rating. His thesis centered on favorable trends in managed care benefiting digital health platforms.
This positive fundamental context encouraged investors to respond decisively to Wednesday’s development.
The stock’s performance stood out particularly given the challenging market conditions that day.
The May 2026 CPI data, released Wednesday morning, revealed headline inflation accelerating to 4.2% year-over-year — the highest reading since 2023 — fueled by surging energy prices linked to geopolitical instability.
The S&P 500, Dow Jones, and Nasdaq all declined during the session in response.
CLOV defied this broader weakness, propelled by a company-specific legal victory with measurable financial impact.
CMS officially notified Clover of the improved 4.5-star rating on June 9, 2026.
